A critical review of anagrelide therapy in essential thrombocythemia and related disorders.

摘要: Thrombocytosis is a common clinical problem and it represents either primary myeloid disorder (a clonal process) or reactive phenomenon. While thrombocytosis often inconsequential, may require cytoreductive therapy to prevent thrombohemorrhagic complications. In this regard, controlled trial has previously demonstrated the efficacy of hydroxyurea in reducing risk thrombosis high-risk patients with essential thrombocythemia (ET). Despite absence similar evidence for benefit, platelet-lowering agent anagrelide been widely used both ET polycythemia vera (PV) recent reports serious side-effects suggest that such practice might be detrimental patients. current review we provide basic drug information as well critical assessment treatment related disorders.